Breakthrough Psoriasis in Patients Receiving Biologicals
Thomas Damsin, Gilles Absil, Florence Libon, Nazli Tassoudji, Arjen F Nikkels Department of Dermatology and Venerology, CHU of Sart Tilman, University of Liège B-4000, Liège, BelgiumCorrespondence: Arjen F Nikkels, Department of Dermatology and Venereology, CHU of Sart Tilman, University of Liège, B...
Saved in:
Main Authors: | Damsin T, Absil G, Libon F, Tassoudji N, Nikkels AF |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Psoriasis: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/breakthrough-psoriasis-in-patients-receiving-biologicals-peer-reviewed-fulltext-article-PTT |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
by: Mario Valenti, et al.
Published: (2025-12-01) -
Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology
by: Tiago Torres, et al.
Published: (2025-12-01) -
Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
by: Haitham M. Saad, et al.
Published: (2024-12-01) -
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
by: Christov S, et al.
Published: (2025-01-01) -
Diagnostic value of interleukins 23 and 17 in the assessment of ulcerative colitis severity
by: M.V. Stoikevych, et al.
Published: (2024-12-01)